ArticleACS catalysis2026
DiploPhos: A Hemilabile Bisphosphine for Sterically Hindered Ni-Catalyzed Suzuki-Miyaura Couplings.
Article in ACS catalysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Pharmaceutically relevant Suzuki-Miyaura cross-couplings (SMCs) often require designer phosphine ligands and palladium loadings above 1 mol% to couple Lewis basic, sterically congested substrates. Recent work has demonstrated that nickel is an attractive alternative to palladium for facile SMCs, but further ligand development is required for Ni catalysis to rival Pd for more challenging couplings. We applied prior work on monophosphine ligand design for Ni to develop a bisphosphine, DiploPhos, that outperforms state-of-the-art ligands for Ni to achieve sterically hindered Ni SMCs with ≥3
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.